导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.22% | 2350/4762 |
| 近一周 | -1.34% | 2040/5451 |
| 近一月 | -7.05% | 4410/5408 |
| 近一季 | 15.69% | 92/5218 |
| 近半年 | 4.57% | 857/4907 |
| 近一年 | -14.82% | 3673/4387 |
| 近两年 | 23.97% | 2546/2950 |
| 近三年 | -7.73% | 2006/2249 |
| 成立以来 | -5.63% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.89% 3447/4961 |
-0.44% 3297/5312 |
- - |
- - |
| 2025 | 8.94% 2886/4813 |
3.65% 1060/3635 |
2.10% 1865/4076 |
22.04% 1709/4524 |
-15.65% 4370/4813 |
| 2024 | -19.27% 2527/3463 |
-14.38% 2522/2808 |
-11.24% 2519/3014 |
17.16% 1254/3129 |
-9.33% 2920/3463 |
| 2023 | -5.36% 731/2656 |
-0.28% 1789/2280 |
-7.80% 1913/2385 |
0.78% 345/2515 |
2.13% 71/2655 |
| 2022 | -22.77% 1085/2207 |
-11.77% 543/1919 |
-3.56% 1828/2016 |
-16.85% 1512/2113 |
9.16% 235/2208 |
| 2021 | -15.21% 1157/1822 |
-4.56% 874/1255 |
8.88% 602/1330 |
-12.24% 1298/1466 |
-7.03% 1561/1822 |
| 2020 | 53.72% 147/1250 |
13.26% 11/1028 |
35.67% 19/1067 |
3.93% 962/1164 |
-3.75% 1134/1184 |
| 2019 | - - |
- - |
- - |
12.45% 33/850 |
4.78% 781/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 国泰中证生物医药ETF联接C VS. 长安沪深300非周期A(740101) |